BEARINGPOINT
22.4.2021 09:57:05 CEST | Business Wire | Press release
Climate change is increasing pressure on companies to take immediate actions to measure, manage, and report greenhouse gas emissions from their operations and value chains. In its recent client story, management and technology consultancy BearingPoint shows how it supported Wipak, a global supplier of packaging solutions and services, in taking a significant step on its journey to reducing its carbon footprint to zero by 2025 by accurately calculating its carbon emissions and gaining transparency across the entire product life-cycle process.
BearingPoint leveraged its Emissions Calculator solution and used a cradle-to-gate approach during a series of workshops to identify Wipak’s key impact areas and aligned them with data requirements. The team then analyzed the processes and data availability for material acquisition, freight transportation, manufacturing sites, warehouses, and support processes related to sales offices and business travel. All data was centralized in a collection plan to feed BearingPoint’s standard data templates, followed by integrating it into the software solution. This resulted in a corporate carbon footprint (CCF), including scopes 1, 2, and 3 according to the Greenhouse Gas Protocol (GHG). Wipak also added the product carbon footprint (PCF) module to support sharing carbon data with clients down to the product level. BearingPoint supported the client to select the allocation methods and relevant secondary data sources, determining every product’s climate impact, from raw material sourcing to their recycling or disposal.
Mika Niemelä, Partner at BearingPoint: “Consumer perception and corporate customers’ demands regarding sustainable packaging are driving Wipak to seek flexible and resource-efficient solutions. At the same time, Wipak needed to ensure accurate carbon footprint calculations to comply with future sustainability regulations and laws, and it now can with our Emission Calculator solution. Today, with our solution, the company is well on its way to achieving a zero-carbon footprint by 2025.”
Wipak can now accurately calculate its carbon emissions that allow for tracking its achievements toward decarbonization on a daily level. Already from the validation phase, the application assesses and summarizes more than 1,400 purchased goods, 3,500 semi-finished products, and 4,700 finished products daily, based on a big data approach.
BearingPoint’s Emissions Calculator also enables the company to make data-driven business decisions toward reducing its carbon footprint to zero by 2025, based on all information centralized in one place and analytic tool-derived insights. The solution offers a comprehensive picture of which region, business line, or product is causing the highest emissions. Wipak also benefits from continuous updates from leading standards such as GHG protocol, ISO 14064, ISO 14067, or GLEC. This ensures that the company is better prepared to meet internal audit requirements, as well as to comply with future sustainability regulations and laws.
Dorit Nelke-Bruhn, Manager Sustainability Processes and Patents, Wipak Group: “To support us on our journey to become the most sustainable flexible packaging company, we were searching for a professional and trusted carbon accounting software to calculate corporate and product carbon footprints. BearingPoint’s Emissions Calculator fulfills our needs. It supports us to assess GHG emissions of raw materials, our production facilities, freight transportation, and support processes such as business travel and sales offices and to identify emission reduction potentials.”
About Wipak Group
Wipak is part of the family owned Wihuri Group, a diverse Finnish conglomerate that can trace its origins back over 100 years. Today the Wihuri group employs 5,000 people with operations in 30 countries.
Wihuri´s Packaging business is one of the world's leading producers of packaging materials and solutions for the Food and Medical supply industries in Europe and North America. Wihuri’s Packaging Division consists of two international brands: WIPAK in Europe and Asia and WINPAK in North America. More information about Winpak can be found below.
Wipak develops and manufactures highly innovative premium-quality flexible packaging solutions for Food products and Medical Instruments and Devices.
www.wipak.com
https://www.linkedin.com/company/wipak/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units. The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business-critical services to its clients, supporting their business success. The third unit provides the software for successful digital transformation. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom